Featured Research

from universities, journals, and other organizations

Autoimmune disease strategy emerges from immune cell discovery

Date:
September 9, 2013
Source:
University of California - San Francisco
Summary:
Scientists have identified a new way to manipulate the immune system that may keep it from attacking the body's own molecules in autoimmune diseases such as Type 1 diabetes, rheumatoid arthritis and multiple sclerosis.

Mark Anderson, MD, PhD, led a team that identified an immune cell, called eTAC cells (shown in green), that may help prevent autoimmune diseases. ETAC cells, which contain a protein in their nucleus called AIRE (shown in red) are relatively rare, and found in lymph nodes and the spleen.
Credit: UC San Francisco

Scientists from UC San Francisco have identified a new way to manipulate the immune system that may keep it from attacking the body's own molecules in autoimmune diseases such as type 1 diabetes, rheumatoid arthritis and multiple sclerosis.

Related Articles


The researchers, led by immunologist Mark Anderson, MD, PhD, a professor with the UCSF Diabetes Center, have discovered a distinctive type of immune cell called an eTAC, which puts a damper on immune responses.

Anderson's research team found that eTACs reside in lymph nodes and spleen in both humans and mice, and determined that they could be manipulated to stop the destruction of the pancreas in a mouse model of diabetes. The study appears in the September issue of the journal Immunity.

Using green fluorescent protein (GFP) to highlight a key regulatory protein called AIRE, Anderson's research team tracked down the rare eTACs and their role in a phenomenon known as peripheral tolerance, which helps prevent autoimmune disease throughout the body.

The newly described immune cells are of a type known as dendritic cells, which make up less than 3 percent of the cells in the immune system. ETAC cells account for a small fraction of all dendritic cells, Anderson said.

Dendritic cells already have been the focus of new cell therapies to treat cancer. These therapies, which include treatments evaluated in clinical trials at UCSF, have been used to prod dendritic cells to rev up a complementary class of immune cells, called T cells. Treatment causes the T cells to target cancer cells, which, despite being abnormal, would not otherwise be subjected to vigorous attack in the same way as foreign microbial invaders.

However, eTAC cells have the opposite effect. Instead of priming T cells to do battle, eTACs counteract the overactive immune response in autoimmune diseases. Anderson's team took advantage of this property to demonstrate that eTACs could prevent autoimmune diabetes in mice.

By displaying "self" molecules to T cells that target them, and turning off these T cells for good, eTACs help the immune system tolerate the molecules naturally present within us, Anderson said.

"The mouse model we are working with involves using T cells that normally attack the islet cells of the pancreas, specifically by recognizing a molecule called chromagranin A that is present on islet cells," Anderson said. "But if the eTACs can get to the T cells first and display chromagranin A, they can prevent T cells from attacking the islets."

Anderson aims to exploit eTACs therapeutically by finding out how to grow them in large numbers outside the body. "We need to figure out how to grow a lot of these cells, to load them up with whatever molecule it is that we want to induce tolerance to, and then to load them back into a patient," he said. "Such a strategy could help selectively shut down an unwanted immune response, such as the anti-islet immune response in type 1 diabetes."

Dendritic cells work with T cells a bit like a sheriff working with a bloodhound. Dendritic cells present not an article of clothing, but rather a specific molecule. If the molecule displayed by the dendritic cell matches the one the T cell was born to target, then that T cell would be activated to expand its numbers and to attack cells or tissues where the molecule is present.

When the interaction is between eTACs and T cells, however, the targeted T cell instead is turned off forever, and never seeks its molecular prey, Anderson said.

The first signal required for activation of a T cell is the display and recognition of the targeted molecule. But a second signal also is required, and eTACs are unable to deliver it, Anderson and colleagues discovered. They lack the molecular arms -- molecules called B7-1 and B7-2 -- needed to hand off the activating message, which are present on other dendritic cells.

The eTACs arise in the bone marrow from adult stem cells that generate the entire blood system, including immune cells, Anderson said. Compared to using pluripotent stem cells of nearly unlimited potential, it should be easier to figure out how to guide the development of eTACs from bone marrow stem cells, he said.

Anderson's search for an immune cell that turns off T cells began with the AIRE protein. Anderson helped discover its function more than a decade ago for specialized cells in the thymus. In the thymus, AIRE plays a key role in central tolerance, the phenomenon whereby immune cells in thymus learn to tolerate the body's naturally occurring molecules shortly after birth. Peripheral tolerance complements central tolerance, and its failure often is responsible for autoimmune diseases that arise long after birth.

Many UCSF faculty members are experts on immune tolerance and autoimmune disease. Another strategy for manipulating the immune system to fight autoimmune disease, pioneered by Jeffrey Bluestone, PhD, the A.W. and Mary Clausen Distinguished Professor of Medicine, Pathology, Microbiology & Immunology at UCSF, already has led to a new treatment being evaluated in a clinical trial for type 1 diabetes. The treatment is based on a type of T cell called the regulatory T cell, which plays a natural role in ending immune responses when infection ends.


Story Source:

The above story is based on materials provided by University of California - San Francisco. Note: Materials may be edited for content and length.


Journal Reference:

  1. JamesM. Gardner, ToddC. Metzger, EileenJ. McMahon, ByronB. Au-Yeung, AnnaK. Krawisz, Wen Lu, JeffreyD. Price, KellseyP. Johannes, AnsumanT. Satpathy, KennethM. Murphy, KristinV. Tarbell, Arthur Weiss, MarkS. Anderson. Extrathymic Aire-Expressing Cells Are a Distinct Bone Marrow-Derived Population that Induce Functional Inactivation of CD4 T Cells. Immunity, 2013; DOI: 10.1016/j.immuni.2013.08.005

Cite This Page:

University of California - San Francisco. "Autoimmune disease strategy emerges from immune cell discovery." ScienceDaily. ScienceDaily, 9 September 2013. <www.sciencedaily.com/releases/2013/09/130909172223.htm>.
University of California - San Francisco. (2013, September 9). Autoimmune disease strategy emerges from immune cell discovery. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2013/09/130909172223.htm
University of California - San Francisco. "Autoimmune disease strategy emerges from immune cell discovery." ScienceDaily. www.sciencedaily.com/releases/2013/09/130909172223.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins